Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors through 2029.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors through 2029
- Authorized capital increased from 375,000,000 to 525,000,000 shares
- Authorized common stock increased from 350,000,000 to 500,000,000 shares, enabling future issuance and potential dilution
- Executive compensation received advisory approval; stockholders favored annual votes with 112,927,161 votes
- Ernst & Young ratified as independent auditor for fiscal 2026 with 173,306,165 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.